Not for use in horses intended for human consumption.

Do not administer by the intra-carotid route.

Careful consideration should be given before administering to animals exposed to stress conditions such as extreme heat, cold, high altitude or fatigue.

Side Effects such as bradycardia, cardiac arrhythmia and polyuria may occur.

Following intravenous administration, a transient rise followed by a fall in blood pressure usually occurs. Should be used with caution when pulmonary disease is suspected.

Sedation is dose dependent and the occurrence of side effects will increase and worsen at higher dosage than recommended.

Chanazine 10% should not be administered in the later stages of pregnancy because of the risk of inducing premature parturition. As the safety of xylazine use during organogenesis has not been fully demonstrated by current methods it should be used with caution during the first month of pregnancy.

For animal treatment only. Keep out of reach of children.

Horses sedated with Xylazine usually remain standing and may still kick with accuracy.

Xylazine is an alpha adrenoceptor agonist acting primarily on alpha-2 receptors. Precaution should be taken to avoid accidental injection/self-injection. Wash splashes from skin and eyes immediately. In the event of accidental injection/self-injection, seek urgent medical advice and show label and other product literature. DO NOT DRIVE as sedation and changes in blood pressure may occur.

Xylazine is an alpha adrenoceptor agonist whose toxicity may cause clinical effects including sedation, respiratory depression and coma, bradycardia and hypotension and hyperglycaemia. Ventricular arrhy- thmias have also been reported. Treatment should be supportive with appropriate intensive therapy.

Unused product and containers should be disposed of in accordance with national requirements.